TY - JOUR
T1 - Heart fat and carotid artery atherosclerosis progression in recently menopausal women
T2 - Impact of menopausal hormone therapy: The KEEPS trial
AU - El Khoudary, Samar R.
AU - Venugopal, Vidya
AU - Manson, Jo Ann E.
AU - Brooks, Maria M.
AU - Santoro, Nanette
AU - Black, Dennis M.
AU - Harman, Mitchell
AU - Hodis, Howard N.
AU - Brinton, Eliot A.
AU - Miller, Virginia M.
AU - Taylor, Hugh S.
AU - Budoff, Matthew J.
N1 - Publisher Copyright:
© 2020 by The North American Menopause Society.
PY - 2020
Y1 - 2020
N2 - Objective:Heart fat deposition has been linked to atherosclerosis, and both accelerate after menopause. Hormone therapy (HT) may differentially slow heart fat deposition and progression of atherosclerosis, depending on the specific HT agent or its route of administration. Our objective was to evaluate the effects of different HT agents, oral and transdermal, on associations between heart fat accumulation and atherosclerosis progression, measured by carotid intima-media thickness (CIMT), in recently menopausal women from the Kronos Early Estrogen Prevention Study (KEEPS) trial.Methods:KEEPS was a randomized, placebo-controlled trial of the effects of 0.45 mg/d oral conjugated equine estrogens (o-CEE) or 50 mcg/d transdermal 17β-estradiol (t-E2), compared with placebo, on 48 months progression of CIMT. Epicardial adipose tissue (EAT) and paracardial adipose tissue (PAT) volumes were quantified by computed tomography.Results:In all, 467 women (mean age [SD] 52.7 [2.5]; 78.2% White; 30% on o-CEE, 30.8% t-E2, 39.2% placebo) with heart fat volumes and CIMT at baseline and 48 months were included. EAT and PAT changes were not associated with CIMT progression; however, the assigned treatment significantly modified the association between PAT (but not EAT) change and CIMT progression. In the o-CEE group, adjusted CIMT progression was 12.66 μm (95% confidence interval [CI] 1.80, 23.52) lower than in t-E2 group (P = 0.02), and 10.09 μm (95% CI 0.79, 19.39) lower than in placebo group (P = 0.03), as per 1-SD increase in PAT.Conclusion:Compared with t-E2, o-CEE appears to slow down the adverse effect of increasing PAT on progression of atherosclerosis. Whether this beneficial association is specific to CEE or to the oral route of CEE administration is unclear and should be assessed further.
AB - Objective:Heart fat deposition has been linked to atherosclerosis, and both accelerate after menopause. Hormone therapy (HT) may differentially slow heart fat deposition and progression of atherosclerosis, depending on the specific HT agent or its route of administration. Our objective was to evaluate the effects of different HT agents, oral and transdermal, on associations between heart fat accumulation and atherosclerosis progression, measured by carotid intima-media thickness (CIMT), in recently menopausal women from the Kronos Early Estrogen Prevention Study (KEEPS) trial.Methods:KEEPS was a randomized, placebo-controlled trial of the effects of 0.45 mg/d oral conjugated equine estrogens (o-CEE) or 50 mcg/d transdermal 17β-estradiol (t-E2), compared with placebo, on 48 months progression of CIMT. Epicardial adipose tissue (EAT) and paracardial adipose tissue (PAT) volumes were quantified by computed tomography.Results:In all, 467 women (mean age [SD] 52.7 [2.5]; 78.2% White; 30% on o-CEE, 30.8% t-E2, 39.2% placebo) with heart fat volumes and CIMT at baseline and 48 months were included. EAT and PAT changes were not associated with CIMT progression; however, the assigned treatment significantly modified the association between PAT (but not EAT) change and CIMT progression. In the o-CEE group, adjusted CIMT progression was 12.66 μm (95% confidence interval [CI] 1.80, 23.52) lower than in t-E2 group (P = 0.02), and 10.09 μm (95% CI 0.79, 19.39) lower than in placebo group (P = 0.03), as per 1-SD increase in PAT.Conclusion:Compared with t-E2, o-CEE appears to slow down the adverse effect of increasing PAT on progression of atherosclerosis. Whether this beneficial association is specific to CEE or to the oral route of CEE administration is unclear and should be assessed further.
KW - Carotid atherosclerosis
KW - Epicardial fat
KW - Estrogen
KW - Menopause
KW - Paracardial fat
UR - http://www.scopus.com/inward/record.url?scp=85081091811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081091811&partnerID=8YFLogxK
U2 - 10.1097/GME.0000000000001472
DO - 10.1097/GME.0000000000001472
M3 - Article
C2 - 32015261
AN - SCOPUS:85081091811
SN - 1072-3714
VL - 27
SP - 255
EP - 262
JO - Menopause
JF - Menopause
IS - 3
ER -